Résultats de recherche
Annie F. Luetkemeyer (born April 13, 1972, Baltimore, Maryland, U.S.) is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco.
Chamie G, Wandera B, Luetkemeyer A, Bogere J, Mugerwa RD, Havlir DV, Charlebois ED. PMID: 23676159. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Professor. HIV, Infectious Disease, and Global Medicine, Infectious Diseases. Interests: HIV therapeutic strategies, COVID-19 treatment and prevention, Sexually Transmitted Infections, DoxyPEP, Viral hepatitis, Hepatitis C, Hepatitis Elimination. Clinical Trials:
Professor. School of Medicine. annie.luetkemeyer@ucsf.edu. +1 415 502-5753. Publications. Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial. JAMA network open. Morris MD, McDonell C, Luetkemeyer AF, Thawley R, McKinney J, Price JC.
Annie Luetkemeyer's 25 research works with 6,553 citations and 2,947 reads, including: Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
CFAR Awards. Comparison of Quantiferon to Conventional Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection (LTBI) in HIV Positive Subjects. Mentored Scientist Award, Spring 2005.
It’s a rare day when Annie Luetkemeyer, MD, puts in fewer than 12 hours at Zuckerberg San Francisco General Hospital. A UCSF physician-researcher, Luetkemeyer previously helped advance effective HIV drugs and a cure for hepatitis C.
